Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
Healthcare
$27.32 -0.91%
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
52W Low $4.31High $57.14
Volume 0.18M
Average 0.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$33.42M
FY 2025 · Annual
Investing Cash Flow
-$578,000.00
FY 2025 · Annual
Financing Cash Flow
$37.42M
FY 2025 · Annual
Cash Flow Statement
EUR
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Depreciation & Amortization | 1.56M | 1.5M | 1.51M | 1.62M | 1.5M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3K |
| Stock-Based Compensation | 3.2M | 3.17M | 3.3M | 4.3M | 3.54M |
| Change in Working Capital | (4.7M) | (606K) | (367K) | 131K | (3.4M) |
| Accounts Receivables | 62K | (101K) | (806K) | (2.07M) | 1.85M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (4.76M) | (505K) | 439K | 2.2M | (5.25M) |
| Other Non-Cash Items | 17.07M | 15.87M | 22.78M | 42.53M | (11.1M) |
| Operating Cash Flow | (29.87M) | (37.1M) | (12.48M) | (19.55M) | (33.42M) |
| Capital Expenditures | (228K) | (92K) | (328K) | (846K) | (546K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (14K) | 230K | (21K) | (109K) | (40K) |
| Investing Cash Flow | (242K) | 138K | (349K) | (955K) | (578K) |
| Debt Repayment | (3.74M) | (4.74M) | (3.62M) | (4.16M) | 38.19M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.44M) | (916K) | 50.39M | (980K) | (2.31M) |
| Financing Cash Flow | (5.18M) | (5.65M) | 46.77M | (5.14M) | 37.42M |
| Effect of Forex Changes | 64K | 83K | (51K) | 94K | (402K) |
| Net Change in Cash | (35.23M) | (42.53M) | 33.9M | (25.55M) | 3.01M |
| Free Cash Flow | (30.1M) | (37.2M) | (12.8M) | (20.4M) | (33.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$24.0M
+ D&A$1.5M
+ Stock-Based Comp$3.5M
+ Deferred Tax$3.0K
- Working Capital-$3.4M
- Other Non-Cash-$11.1M
= Operating Cash Flow-$33.4M
- Capex-$546.0K
= Free Cash Flow-$34.0M
Analysis
FY2025 free cash flow is -$34.0M. FCF conversion is 141.8% of net income. Operating cash flow was -$33.4M, with capex of -$546.0K. The largest bridge item is Other Non-Cash at -$11.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Oct 26, 2026 | |
| 6-K | 6-K filing | Oct 20, 2026 | |
| 6-K | 6-K filing | Oct 1, 2026 |
Does NBTX generate free cash flow?
Nanobiotix S.A. (NBTX) generated -$33.97M of free cash flow in fiscal 2025.
How much operating cash flow does NBTX produce?
Operating cash flow was -$33.42M, before capital expenditures of $546,000.00.
Continue the stock analysis
Jump to another research area for this company.